CAR T-Cell Therapy Hits Prime Time; Challenges Remain – Targeted Oncology
Targeted Oncology |
CAR T-Cell Therapy Hits Prime Time; Challenges Remain
Targeted Oncology Chimeric antigen receptor (CAR) T cells have hit the prime time, with 2 FDA approvals already for this class of cellbased therapy. Undoubtedly this will be a game changer for patients with B-cell malignancies who have a small number of treatment … Bluebird Bio's CAR T-Cell Therapy Stopped Progression of Hard-to-Treat Myeloma |
